Contrast-Enhanced Spectral Mammography in Women With Intermediate Breast Cancer Risk and Dense Breasts

2018 ◽  
Vol 211 (5) ◽  
pp. W267-W274 ◽  
Author(s):  
Vera Sorin ◽  
Yael Yagil ◽  
Ady Yosepovich ◽  
Anat Shalmon ◽  
Michael Gotlieb ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Dense Breasts ◽  
Contrast Enhanced

Glandular Tissue Component and Breast Cancer Risk in Mammographically Dense Breasts at Screening Breast US

Radiology ◽  
2021 ◽  
pp. 210367
Author(s):  
Su Hyun Lee ◽  
Han-Suk Ryu ◽  
Myoung-jin Jang ◽  
Ann Yi ◽  
Su Min Ha ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Glandular Tissue ◽  
Tissue Component ◽  
Dense Breasts

scholarly journals Discussions of Dense Breasts, Breast Cancer Risk, and Screening Choices in 2019

JAMA ◽  
2019 ◽  
Vol 322 (1) ◽  
pp. 69 ◽  
Author(s):  
Karla Kerlikowske ◽  
Diana L. Miglioretti ◽  
Celine M. Vachon
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Dense Breasts

Determination of breast density by bioimpedance.

2012 ◽  
Vol 30 (27_suppl) ◽  
pp. 56-56
Author(s):  
Karina Bukhanov ◽  
Joel S. Ironstone ◽  
Cindy Basso ◽  
Tina Bilodeau
Keyword(s):  
Breast Cancer ◽  
Primary Care ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Correlation Coefficient ◽  
Breast Density ◽  
Pearson Correlation ◽  
Mammographic Breast Density ◽  
Pearson Correlation Coefficient ◽  
Dense Breasts

56 Background: Mammographic breast density is a significant risk factor for breast cancer. Women with extremely dense breasts are at 4-to-6 times the risk of developing breast cancer than women with primarily fatty breast tissue. Electrical Breast Densitometry (EBD) is a new technique that assesses breast density. EBD is non-ionizing, fast, has low cost per test ($20-$30) and may help in breast cancer risk assessment in the primary care setting. Methods: This study evaluated the feasibility of the EBD in an IRB-approved pilot study of 20 patients. The study used a custom-made self-adhesive electrode (SenoSENSE Medical Systems, Toronto, Canada) interfaced to an off-the-shelf impedance meter (Bodystat 1500, Bodystat, Isle of Man, UK) with a customized cable. On the same day as the subject’s scheduled mammogram, impedance measurements were acquired for each breast. Mammogram densities were scored by a trained radiologist using standard BiRADS breast density categories 1 to 4. Results: A high correlation coefficient was observed (Pearson correlation coefficient >0.80) between breast density determined by the EBD and the BiRADS breast density score. In addition a statistically significant difference was observed between dense categories (BiRADS 3,4) and fatty categories (BiRADS 1,2) (p<0.01), as well as between extremely dense breasts (BiRADS 4) and all other categories (p<0.01). Very high correlation (Pearson correlation coefficient >0.95) was observed between EBD measurements on the left and right breasts. Previous studies have reported a left/right correlation of 0.89 for blinded mammography readers. Conclusions: These results suggests that the EBD measure may be less variable than mammographic estimates of density. The results of the study suggest that Electrical Breast Densitometry is a promising technique for the assessment of breast density and the ability to aid in evaluation of breast cancer risk. It can be reasonably deployed at primary care facilities.

scholarly journals Qualitative Assessments of Density and Background Parenchymal Enhancement on Contrast-Enhanced Spectral Mammography Associated with Breast Cancer Risk of High-Risk Women

2020 ◽  
Author(s):  
Ning Mao ◽  
Ping Yin ◽  
Fan Lin ◽  
Zhongyi Wang ◽  
Ping Yang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
High Risk Women ◽  
Background Parenchymal Enhancement ◽  
Contrast Enhanced ◽  
History Of ◽  
Parenchymal Enhancement

Abstract Background: To investigate the correlation between the risk of developing breast cancer for high-risk women and the density and background parenchymal enhancement (BPE) on contrast-enhanced spectral mammography (CESM).Methods: This retrospective study was approved by the Institutional Review Board of our hospital. Women at high risk, without breast cancer history and received CESM examination from July 2016 to December 2017 were retrospectively enrolled. Patients who developed breast cancer after CESM examination were classified as cancer cohorts, and women who did not develop breast cancer with maximized follow-up time were categorized as control cohorts. These two cohorts were one-to-one matched in age, family and/or genetic history of breast cancer, and BRCA status. The density and amount of BPE at CESM imaging were assessed. Conditional logistic regression was applied to evaluate the relationship between imaging features and breast cancer risk. Results: During the follow-up interval, 90 women at high risk with no history of breast cancer were diagnosed with breast cancer (invasive, n = 46; in situ, n = 44). During follow-up, women with mild, moderate or significant BPE were seven times more likely to be diagnosed with breast cancer than women with minimal BPE [P = 0.005; odds ratio (OR) = 7.0; 95% confidence interval(CI): 1.1-71.1]. Breast density was not significantly different between the two cohorts (P = 0.5). Conclusions: Increased BPE levels increase the risk of breast cancer among high-risk women.

scholarly journals MRI versus Mammography plus Ultrasound in Women at Intermediate Breast Cancer Risk: Study Design and Protocol of the MRIB Multicenter, Randomized, Controlled Trial

Diagnostics ◽  
2021 ◽  
Vol 11 (9) ◽  
pp. 1635
Author(s):  
Luigina Ada Bonelli ◽  
Massimo Calabrese ◽  
Paolo Belli ◽  
Stefano Corcione ◽  
Claudio Losio ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Randomized Controlled Trial ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Controlled Trial ◽  
Hormone Replacement ◽  
Dense Breasts ◽  
Randomized Controlled ◽  
Multicenter Randomized Controlled Trial

In women at high/intermediate lifetime risk of breast cancer (BC-LTR), contrast-enhanced magnetic resonance imaging (MRI) added to mammography ± ultrasound (MX ± US) increases sensitivity but decreases specificity. Screening with MRI alone is an alternative and potentially more cost-effective strategy. Here, we describe the study protocol and the characteristics of enrolled patients for MRIB feasibility, multicenter, randomized, controlled trial, which aims to compare MRI alone versus MX+US in women at intermediate breast cancer risk (aged 40–59, with a 15–30% BC-LTR and/or extremely dense breasts). Two screening rounds per woman were planned in ten centers experienced in MRI screening, the primary endpoint being the rate of cancers detected in the 2 arms after 5 years of follow-up. From July 2013 to November 2015, 1254 women (mean age 47 years) were enrolled: 624 were assigned to MX+US and 630 to MRI. Most of them were aged below 50 (72%) and premenopausal (45%), and 52% used oral contraceptives. Among postmenopausal women, 15% had used hormone replacement therapy. Breast and/or ovarian cancer in mothers and/or sisters were reported by 37% of enrolled women, 79% had extremely dense breasts, and 41% had a 15–30% BC-LTR. The distribution of the major determinants of breast cancer risk profiles (breast density and family history of breast and ovarian cancer) of enrolled women varied across centers.

Sign in / Sign up

Export Citation Format

Share Document